Rachel V Marini

TL;DR: There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections and across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics.

TL;DR: Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam and one patient developed a recurrent infection due to ompK36 porin mutant Klebsiellapneumoniae.

TL;DR: Isavuconazole was effective and well-tolerated as antifungal prophylaxis following lung transplantation and IFIs were associated with increased mortality and longer hospitalizations.

TL;DR: Moderate interpatient variability in isavuconazole Exposure, the identification of factors associated with lower exposure, the recognition that Ctrough is a surrogate marker for AUC, and the availability of a simple analytical method suggest that therapeutic drug monitoring (TDM) may be useful for guiding treatment in at least some SOT recipients.

TL;DR: Standard ISA dosing is likely to attain the PK-pharmacodynamic target (area under the concentration curve/MIC ratio [AUC/MIC]) for treatment effectiveness against almost all infections caused by Aspergillus fumigatus isolates exhibiting MICs of ≤0.5 μg/ml (modal MIC).